Literature DB >> 9119852

Loss to follow-up matters.

D W Murray1, A R Britton, C J Bulstrode.   

Abstract

Survival analysis of joint replacement relies on the assumption that surgical procedures in patients lost to follow-up have the same chance of failing as those in patients who continue to be assessed. Our study questions that assumption. During the 16-year follow-up of 2268 patients who had received total hip replacements 142 (6%) were lost to follow-up. The cumulative loss at 15 years was 20%. At their last assessment, patients who subsequently failed to attend for follow-up had significantly worse pain, range of movement and opinion of their progress (p < 0.001) and significantly worse radiological features than a matched control group (p < 0.01). Patients lost to follow-up have a worse outcome than those who continue to be assessed. Consequently, a survival analysis that does not take into account such patients is likely to give falsely optimistic results. It is therefore essential that vigorous attempts are made to minimise loss to follow-up, and that the rate of such loss is quoted. The overall loss to follow-up disguises the magnitude of the problem, which is best quantified by a cumulative rate of follow-up. The reliability of a study can be assessed by a loss-to-follow-up quotient, calculated by the number of failures: the lower the quotient the more reliable the data. Ideally, the quotient should be less than 1.

Entities:  

Mesh:

Year:  1997        PMID: 9119852     DOI: 10.1302/0301-620x.79b2.6975

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  61 in total

1.  Total knee replacement: the joint of the decade. A successful operation, for which there's a large unmet need.

Authors:  C G Moran; T C Horton
Journal:  BMJ       Date:  2000-03-25

2.  The survival and fate of acetabular reconstruction with impaction grafting for large defects.

Authors:  Eduardo Garcia-Cimbrelo; Ana Cruz-Pardos; Eduardo Garcia-Rey; José Ortega-Chamarro
Journal:  Clin Orthop Relat Res       Date:  2010-12       Impact factor: 4.176

3.  Cochlear Implant Reliability: On the Reporting of Rates of Revision Surgery.

Authors:  Graham O'Neill; Neil S Tolley
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2020-04-01

4.  [The cemented MS-30 stem. A multi-surgeon series of 333 consecutive cases].

Authors:  M Clauss; T Reitzel; M Pritsch; U J Schlegel; R G Bitsch; V Ewerbeck; H Mau; S J Breusch
Journal:  Orthopade       Date:  2006-07       Impact factor: 1.087

5.  Ten-year survival analysis of the PFC total knee arthroplasty--a surgeon's first 99 replacements.

Authors:  Alasdair J A Santini; Videsh Raut
Journal:  Int Orthop       Date:  2007-03-16       Impact factor: 3.075

6.  How to deal with lost to follow-up in total knee arthroplasty : a new method based on the competing risks approach.

Authors:  Klaas-Auke Nouta; Bart G Pijls; Marta Fiocco; J Christiaan Keurentjes; Rob G H H Nelissen
Journal:  Int Orthop       Date:  2013-12-05       Impact factor: 3.075

7.  THA with the ABG I prosthesis at 15 years. Excellent survival with minimal osteolysis.

Authors:  P N Baker; I A McMurtry; G Chuter; A Port; J Anderson
Journal:  Clin Orthop Relat Res       Date:  2010-07       Impact factor: 4.176

Review 8.  Correlation between patient age at total hip replacement surgery and lifeexpectancy.

Authors:  Carlos Roberto Schwartsmann; Leandro de Freitas Spinelli; Leonardo Carbonera Boschin; Anthony Kerbes Yépez; Marcus Vinicius Crestani; Marcelo Faria Silva
Journal:  Acta Ortop Bras       Date:  2015 Nov-Dec       Impact factor: 0.513

9.  Patients with implants should be given implant cards. Intraocular lens implant cards contain inadequate clinical data.

Authors:  T Eke; E Rom; A A Castillo
Journal:  BMJ       Date:  1998-04-18

10.  Good results with cemented total hip arthroplasty in patients between 40 and 50 years of age.

Authors:  Daniël C J de Kam; Jean W M Gardeniers; René P H Veth; B Willem Schreurs
Journal:  Acta Orthop       Date:  2010-04       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.